Fate Therapeutics Inc (FATE)

[jondoeuk]

During this half, they will take the opportunity to showcase their leadership in the development of iPSC-derived NK and T-cell therapies, including at SITC and ASH.

At SITC, will highlight clinical progress and innovation under the solid tumour franchise where they continue to invest in building a deep pipeline of multiplexed engineered CAR-NK and T-cell product cadets. This includes the development and incorporation of new synthetic elements designed to overcome critical barriers that limit the effectiveness of cell therapies, such as cell homing, escape and the immunosuppressive tumour microenvironment. Also, expect to present new preclinical data for the ADR tech and highlight its integration into a next-gen NK cell product candidate.